The present study demonstrates that circOMA1 attenuates CAB efficacy through ferroptosis resistance and may be a new therapeutic target for the individualized treatment of DA-resistant prolactinoma patients.
CircOMA1 modulates cabergoline resistance by downregulating ferroptosis in prolactinoma.